London-based LabGenius raises over €40.1 million to further develop its ML-driven antibody discovery platform

London-based LabGenius, a drug discovery company pioneering the use of machine learning for the discovery of novel therapeutic antibodies, today announced that it has closed a Series B financing round of over €40.1 million. The investment brings LabGenius’ total funding to date to more than €67.8 million.